Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | LIPE | Q05469 | 5/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085374 | 0.81 | ROCK2 (0.49) | SCDROCK2USP30FFAR1PRMT5 | |
| SCHEMBL3089708 | 0.80 | SCD (0.43) | SCDROCK2USP30FFAR1RET | |
| SCHEMBL30483039 | 0.80 | SCD (0.43) | SCDROCK2USP30FFAR1RET | |
| SCHEMBL29998967 | 0.79 | ROCK2 (0.38) | SCDROCK2USP30SCN9AFFAR1 | |
| SCHEMBL15476193 | 0.79 | ROCK2 (0.38) | SCDROCK2USP30SCN9AFFAR1 | |
| SCHEMBL141413 | 0.78 | FFAR1 (0.52) | SCDROCK2USP30FFAR1UCHL1 | |
| SCHEMBL31627089 | 0.78 | PDPK1 (0.39) | SCDPRMT5WDR77 | |
| SCHEMBL22165763 | 0.77 | ROCK2 (0.48) | SCDROCK2SCN9A | |
| SCHEMBL20509718 | 0.77 | ROCK2 (0.48) | SCDROCK2SCN9ARETUCHL1 | |
| SCHEMBL32685024 | 0.76 | SCD (0.39) | SCDUSP30LIPEPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | SCD 4877/4885ROCK2 332/4885USP30 4053/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | SCD 4877/4885ROCK2 332/4885USP30 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.